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Abstract
To elucidate the prevalence, characteristics and risk factors of community-onset Clostridium difﬁcile infection (CO-CDI), an uncontrolled
prospective study was performed. For 3 months in 2007–2008, three laboratories in The Netherlands tested all unformed stool samples
submitted by general practitioners (GPs) for C. difﬁcile by enzyme immunoassay for toxins A and B, irrespective of whether GPs speciﬁ-
cally requested this. Patients with positive results were asked to complete a questionnaire. Positive stool samples were cultured for
C. difﬁcile, and isolates were characterized. In all, 2443 stool samples from 2423 patients were tested, and 37 patients (1.5%) with posi-
tive toxin test results were identiﬁed. Mixed infections were not found. Age varied from 1 to 92 years, and 18% were under the age of
20 years. Diarrhoea was typically frequent and watery, sometimes with admixture of blood or fever. Eight of 28 patients (29%) suffered
recurrences. Among 31 patients with toxin-positive stool samples for whom information was available, 20 (65%) had not been admitted
to a healthcare institution in the year before, 13 (42%) had not used antibiotics during the 6 months before, and eight (26%) had neither
risk factor. A separate analysis for patients whose samples were both toxin-positive and culture-positive produced similar results. Cul-
tured C. difﬁcile isolates belonged to 13 different PCR ribotypes, and 24% of the isolates were non-typeable (rare or new) PCR ribo-
types. In conclusion, CO-CDI can affect all age groups, and many patients do not have known risk factors. Several PCR ribotypes not
encountered in hospital-associated outbreaks were found, suggesting the absence of a direct link between outbreaks and community-
onset cases.
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Introduction
Previously identiﬁed risk factors for Clostridium difﬁcile infec-
tion (CDI) include admission to hospital or nursing home,
old age, chronic comorbidity, longer hospital stay, antibiotic
usage and prior chemotherapy [1], use of gastric acid sup-
pressants, and nasogastric tubes. Since early 2003, both the
incidence and the severity of CDI appear to have increased.
This has been ascribed at least partly to the emergence of
the new strain, PCR ribotype 027. In 2007, PCR ribotype
027 was found in stool samples of 25% of patients with nos-
ocomial CDI in The Netherlands [2].
The incidence of CDI occurring outside healthcare facili-
ties, usually termed community-onset CDI (CO-CDI), may
be rising as well [3–10]. Some of the reported cases of
CO-CDI may be truly community-acquired, but many cases
may actually be linked to healthcare institutions. CO-CDI
has never been investigated with detailed characterization of
C. difﬁcile isolates. In the present study, we aimed to investi-
gate both the clinical characteristics and the source of CO-
CDI in three areas in The Netherlands where outbreaks of
nosocomial CDI due to PCR ribotype 027 had recently
occurred. We screened all stool samples submitted by gen-
eral practitioners (GPs) for C. difﬁcile, characterized the cul-
tured C. difﬁcile isolates, and obtained patient information
using a standardized questionnaire.
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Materials and Methods
Three medical microbiological laboratories in The Nether-
lands participated, namely SALTRO Artsenlaboratorium
in Utrecht (providing services for 900 GPs), Public Health
Laboratory Kennemerland in Haarlem (400 GPs), and the
Laboratory for Medical Microbiology and Infectious Diseases
in Zwolle (195 GPs). All unformed stool samples submitted
by GPs during a period of 3 months were tested for C. difﬁ-
cile, using a commercially available rapid enzyme immunoas-
say (EIA) for C. difﬁcile toxins A and B (ICTAB; Meridian
Bioscience, Cincinnati, OH, USA). Samples were assayed
irrespective of the diagnostic tests requested by the GP. If a
stool sample gave positive results and the corresponding
patient had no earlier positive stool sample, this patient was
included in our study.
Microbiological tests
If a stool sample gave positive results, the sample was cul-
tured at the regional laboratory and isolates were sent to
the reference laboratory at the Leiden University Medical
Centre. All isolates were genetically identiﬁed as C. difﬁcile
by an in-house PCR for the presence of the gluD gene
speciﬁc for C. difﬁcile [7]. C. difﬁcile isolates were charac-
terized by PCR ribotyping [11]. The presence of tcdA, tcdB
and binary toxin genes was investigated as described previ-
ously [2]. Antimicrobial susceptibility was determined by
Etest for erythromycin, clindamycin, moxiﬂoxacin and
ciproﬂoxacin, using the breakpoints recently described
[12].
Clinical and epidemiological information
The laboratories collected demographic data from all
patients whose stool samples were submitted by GPs. If a
stool sample gave positive results, the GP who had submit-
ted the sample was asked to give the patient an envelope
containing information on the background and aim of our
study, together with a request to complete a web-based or
printed questionnaire.
The patients were asked for information concerning their
symptoms, treatment and possible risk factors. The question
about stool consistency on the day of maximal illness was
illustrated by drawings from the Bristol Stool Scale [13]. We
chose to enquire about antibiotic use during the 6 months
prior to diarrhoea instead of 3 months, because we wanted
to rule out damage to the colonization barrier persisting for
longer than 3 months after the use of antibiotics. It is unclear
how long this damage may persist but, in animal models, per-
sisting susceptibility to C. difﬁcile colitis 74 days after one
dose of clindamycin has been described [14]. If the patient
could not or did not respond, we asked the GPs for the
most essential patient information.
In June 2008, we asked the GPs of all included patients for
information on persistent diarrhoea attributed to CDI,
recurrences and deaths. The diagnosis of a recurrence was
left to the judgement of the GPs.
Statistical analysis
Data were analysed with SPSS 14.0 for Windows (SPSS
Inc., Chicago, IL, USA). Descriptive statistics and Maentel–
Haenszel-adjusted ORs were used to examine possible
correlations. Non-normally distributed continuous variables
were compared with the Mann–Whitney U-test.
Results
In total, 2443 stool samples from 2423 patients were submit-
ted by GPs. Thirty-seven (1.5%) patients with positive
samples were identiﬁed. Of all 419 samples from patients
aged 65 years or older, 19 (4.5%) were toxin-positive. The
laboratories in Utrecht and Zwolle registered whether GPs
explicitly requested testing for C. difﬁcile. This was the case
in 12 of 32 positive stool samples.
Twenty-one patients completed a questionnaire. Informa-
tion on ten of the remaining 16 patients was obtained from
their GPs. We obtained follow-up information on 25 patients
from their GPs in June, 2008.
Co-infection and characterization of the isolates
Co-infection of CDI with other enteropathogens was not
found. Thirteen different PCR ribotypes were found, and
seven strains could not be characterized by PCR ribotyping
(Table 1). No C. difﬁcile could be cultured from stool samples
of ﬁve patients (14%), and the stools of three patients (8%)
were not cultured, because of logistical errors. As these
eight patients may have had false-positive stool toxin test
results, we performed the analysis for all patients and for
patients who had a positive culture. In spite of the fact that
outbreaks due to the strain PCR ribotype 027 had occurred
in all regions, this PCR ribotype was not found in the com-
munity.
Different PCR ribotypes were not clearly linked to an
age group or region, except for PCR ribotype 078, which
was found four times in the region of Zwolle but not in
either of the other regions. The numbers of patients in
each speciﬁc PCR ribotype group were very small, limiting
the possibility of ﬁnding associations with clinical
characteristics.
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Five of seven unknown PCR ribotypes belonged to
patients who had not been admitted to a hospital or nursing
home and who were not employed in healthcare. A sixth
patient had been admitted both to a hospital and to a nurs-
ing home, and for the seventh patient this information was
not available.
The isolates were tested for antimicrobial susceptibility
and production of binary toxin (Table 1). Genes for binary
toxin production were found in four isolates, which belonged
to PCR ribotype 023 or 078, both of which have been asso-
ciated with binary toxin production.
Clinical characteristics and follow-up information
Clinical patient characteristics are listed in Table 2. Median
ages of the patients with positive and with negative toxin
stool tests were signiﬁcantly different (54 years; (range, 1–
92 years) and 37 years (range, 0–97 years), respectively;
p <0.001). Symptoms were serious, with watery consistency,
high stool frequency and often fever (24%) and admixture of
blood (33%), and patients were usually treated (86%). The
recurrence rate was high, with eight (29%) of patients suffer-
ing recurrences and one patient (4%) still suffering from diar-
rhoea on follow-up. Of those eight patients who suffered
recurrence, six suffered one recurrence, one suffered two
recurrences, and one suffered four recurrences. Four of 32
patients had died. Three deaths were deemed by the GPs
not to be attributable to CDI, and for one death this infor-
mation was not available.
Risk factors
The risk factors that we investigated are listed in Table 3.
Only 35% of patients had been admitted to healthcare facili-
ties, and only 58% had used antibiotics during the 6 months
before diarrhoea developed. This percentage was similar
among those who had been admitted (55%) and those who
had not (60%). The antibiotics mentioned most often were
amoxycillin–clavulanic acid (nine patients) and amoxycillin
(four other patients).
Most patients had comorbidity, as judged by the fact that
21 of 31 (68%) used medication and 13 of 21 (62%) reported
being monitored by a medical specialist. When two patients
who used only a selective serotonin re-uptake inhibitor for a
mood disorder and one patient who used only acetamino-
phen for pain because of osteoporosis were excluded, the
percentage of patients who used medication fell to 58. Use
of medication was associated with older age groups, but not
restricted to these groups (lowest age quartile, none of six
patients; both middle quartiles, two of nine patients; highest
quartile, seven of seven patients). Gastric acid suppressants
were used by 26% of patients. No patient was found to have
a profession involving contact with farm animals.
Discussion
In this study of clinical and microbiological characteristics of
CO-CDI, the prevalence of CDI among patients with commu-
nity-onset diarrhoea for which microbiological diagnostics
were requested amounted to 1.5%. In most cases, there was
no speciﬁc request to test for C. difﬁcile, which would have
caused six of ten cases to be missed. The clinical picture of the
disease was severe, with a high recurrence rate. We found no
link to healthcare facilities in the majority of cases. Moreover,
of the patients who were not admitted to healthcare institu-
TABLE 1. PCR ribotypes found at various regional laboratories, followed by number (%) of isolates that contained binary toxin
genes and number (%) that were resistant to various antibiotics
PCR ribotype
Number of
isolates
Binary
toxin
Moxiﬂoxacin-
resistant
Ciproﬂoxacin-
resistant
Erythromycin-
resistant
Clindamycin-
resistant
002 1 0 0 1 (100) 1 (100) 0
014 3 0 0 3 (100) 1 (33) 1 (33)
015 2 0 0 2 (100) 0 0
023 1 1 (100) 0 1 (100) 0 0
025 1 0 0 1 (100) 1 (100) 0
043 1 0 0 1 (100) 0 0
044 1 0 0 1 (100) 1 (100) 0
067 1 0 0 1 (100) 0 0
078 4 3a (75) 0 4 (100) 2 (50) 1 (25)
081 1 0 1 (100) 1 (100) 0 0
110 1 0 0 1 (100) 1 (100) 0
117 2 0 1 (50) 2 (100) 0 0
172 3 0 0 3 (100) 0 0
Unknown ribotype 7 0bc 0 6 (100)b 1 (17)c 0
No Clostridium difﬁcile was cultured 5
No culture was performed 3
aTwo isolates contained only the gene for CdtA, and not the gene for CdtB.
bOne isolate did not contain the genes for TcdA or TcdB.
cOne isolate was not available for binary toxin and susceptibility testing.
CMI Bauer et al. Community-onset CDI in The Netherlands 1089
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1087–1092
tions, 40% had not used antibiotics during the 6 months prior
to the development of diarrhoea. Furthermore, 42% of all
patients did not use medication compatible with relevant com-
orbidity, and 18% were under 20 years of age. Finally, most of
the PCR ribotypes found were not associated with outbreaks
in healthcare institutions. In particular, PCR ribotype 027 was
not found, in spite of the fact that, in all of these areas, out-
breaks with this PCR ribotype had recently occurred.
Methodological issues might have affected the results of
this study. First, our study population was based on stool
samples that were submitted by GPs, which may have led to
referral bias. In The Netherlands, GPs are encouraged by
their guidelines to culture stools when there is serious illness
[15]. Therefore, it is possible that CO-CDI can run a much
milder self-limiting course, in which no diagnostic tests are
performed. Second, we screened for cases with an EIA for
toxins A and B, and test characteristics will have inﬂuenced
the population identiﬁed. EIAs may be relatively insensitive in
comparison with stool culture and cytotoxicity assays [16].
We used an immunochromatography assay (ICTAB;
Meridian) that has been shown to have a sensitivity of 91%, a
speciﬁcity of 97%, a positive predictive value of 70% and a
negative predictive value of 99% in comparison with the
cytotoxicity assay used as the reference standard [17]. How-
ever, the characteristics of this assay were determined in a
population of hospitalized patients, and it is unknown
whether these characteristics may be extrapolated to a com-
munity setting. The design of the study was not optimized
for a high recovery rate of C. difﬁcile cultures, as each centre
was allowed to apply its own culture protocol. This may
TABLE 2. Clinical characteristics of Clostridium difﬁcile infec-
tion (CDI) (sums of percentages may amount to more than
100, because of rounding)
Toxin-
positive
Toxin-positive
and
culture-positive
Characteristic (continuous variables)
Age (years), median (range) 54 (1–92) 69 (1–92)
Interval between start of
diarrhoea and stool test (days)a
10 (5–65) 12 (7–65)
Characteristic (categorical variables), proportion (%)
Age category (years)
0–4 2/37 (5) 1/29 (3)
5–9 1/37 (3) 1/29 (3)
10–14 2/37 (5) 2/29 (7)
15–19 2/37 (5) 2/29 (7)
20–39 4/37 (11) 2/29 (7)
40–59 8/37 (22) 4/29 (14)
60–79 8/37 (22) 8/29 (28)
‡80 10/37 (27) 9/29 (31)
Female sex 20/37 (54) 16/29 (55)
Stool consistency on the day of maximal illness
Formed 1/21 (5) 1/16 (6)
Mushy 1/21 (5) 1/16 (6)
Watery 19/21 (90) 14/16 (88)
Stool frequency on the day of maximal illness (times per day)
1–3 2/21 (10) 1/16 (6)
4–6 7/21 (33) 5/16 (31)
7–10 5/21 (24) 4/16 (25)
>10 7/21 (33) 6/16 (38)
Admixture of blood with
stools on any day
7/21 (33) 4/16 (25)
Abdominal pain on any day 14/21 (67) 9/16 (56)
Temperature over 38C on any day 5/21 (24) 3/16 (19)
Treatment
Metronidazole 16/21 (76) 13/16 (81)
Metronidazole, followed by vancomycin 2/21 (10) 2/16 (13)
No treatment 3/21 (14) 1/16 (6)
Course of diarrhoea
Recovery from diarrhoea
without antibiotics
9/28 (32) 7/22 (32)
Recovery from diarrhoea
after one treatment
10/28 (36) 8/22 (36)
Recovery from treatment
after ‡1 recurrences
8/28 (29) 7/22 (32)
Persistent diarrhoea 1/28 (4) 0/22 (0)
Mortality
Died 4/32 (13) 4/25 (16)
Death partially attributable to CDI 0/31 (0) 0/24 (0)
aOf the 21 patients who ﬁlled in the questionnaire.
TABLE 3. Proportions (%) of patients with risk factors for
Clostridium difﬁcile infection
Risk factor Toxin-positive
Toxin-positive
and
culture-positive
Hospital admission in the year
prior to diarrhoea
9/31 (29) 8/25 (32)
Hospital admission in the year
prior to diarrhoea and/or
admission to a nursing home
in the year prior to diarrhoea
6/31 (19) 6/25 (24)
No admission to healthcare
institutions in the year prior
to diarrhoea
20/31 (65) 15/25 (60)
Employment in healthcare 1/31 (3) 0/25 (0)
No admission to healthcare
institutions in the year prior
to diarrhoea or employment
in healthcare
19/31 (61) 15/25 (60)
Family members employed
in healthcare
4/21 (19) 3/16 (19)
Hospital admission of family
members in the year prior
to diarrhoea
2/21 (10) 2/16 (13)
Visit to a nursing home in the
year prior to diarrhoea
4/21 (19) 3/16 (19)
No link to healthcare institutions
(as assessed by the above variables)
9/21 (43) 6/16 (38)
Antibiotics during the 6 months
prior to diarrhoea
18/31 (58) 16/25 (64)
Antibiotics during the 6 months
prior to diarrhoea of those not
admitted to healthcare institutions
in the year prior to diarrhoea
12/20 (60) 11/15 (73)
No admission to healthcare
institutions in the year prior to
diarrhoea or employment in
healthcare or antibiotics during
the 6 months prior to diarrhoea
7/31 (23) 4/25 (16)
Family members who experienced
diarrhoea during the month prior
to diarrhoea
5/19 (26) 4/14 (29)
Use of medication 21/31 (68) 15/25 (60)
Use of medication compatible with
relevant comorbidity
18/31 (58) 14/25 (56)
Use of corticosteroids 0/31 (0) 0/25 (0)
Use of antiperistaltic agents 1/31 (3) 0/25 (0)
Use of gastric acid suppressants 8/31 (26) 7/25 (28)
Monitoring by a medical specialist
(including nursing home physician)
13/21 (62) 12/16 (75)
Pet ownership 6/21 (29) 4/16 (25)
Professional contact with farm animals 0/31 (0) 0/25 (0)
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have resulted in the 14% toxin-positive and culture-negative
stool samples. Alternatively, EIAs of these samples may have
been falsely positive. Therefore, we analysed results from
toxin-positive and culture-positive samples in a separate anal-
ysis. Third, bias may have been introduced by the manner in
which clinical data were gathered. Part of the information
came from questionnaires, which were completed by 21 of
37 patients. Possibly, the severity of diarrhoea or comorbidi-
ty of patients who completed the questionnaire differed from
those who did not.
In spite of this possible bias, we feel that the strength of
the study is the detail of the information that we did obtain.
Most previous studies lack this detail, and no other study
has investigated the follow-up of patients with CO-CDI.
Moreover, we characterized C. difﬁcile isolates by ribotyping,
which serves as an extra tool with which to investigate
epidemiological associations.
Most studies on CO-CDI lack a clear deﬁnition of what is
to be considered community-acquired. Often, CDI is desig-
nated as community-acquired when stool samples were
collected in the community without knowledge of the
patient’s prior healthcare contacts. The European Centre for
Disease Prevention and Control and the CDC have arbi-
trarily divided CO-CDI (and nosocomial CDI during the ﬁrst
48 h of the admission) into community-onset healthcare facil-
ity-associated (CO-CDI occurring within 4 weeks after dis-
charge from a healthcare facility) and community-acquired
(occurring after 12 weeks after discharge) [18,19], leaving an
intermediate period. Using these deﬁnitions, Kutty et al. [20]
found many CO-CDI cases to be community-onset health-
care facility-associated, suggesting that they were not actually
acquired in the community, but in healthcare facilities. Only
17% of CO-CDI cases in a Dutch hospital-based surveillance
study were community-acquired when the deﬁnitions of the
European Centre for Disease Prevention and Control were
applied [7]. The detail of the clinical information that we
obtained allows for a clear distinction between CDI that is
truly community-acquired and CDI that may have been
acquired in healthcare facilities.
Furthermore, studies investigating CO-CDI seldom use
molecular characterization of C. difﬁcile isolates as an addi-
tional epidemiological tool. A Canadian study [21] character-
ized 17% of C. difﬁcile strains from community sources as
PCR ribotype 027, but no clinical data were available to ver-
ify that the patients had not been recently admitted to
healthcare institutions.
A recent surveillance study by the CDC [10] found results
very similar to ours. However, in this investigation, unlike
ours, patients were not systematically surveyed and PCR
ribotyping was not performed.
Finally, a recent case–control study in the UK [22] investi-
gated the prevalence and clinical characteristics of patients
with cytotoxin-positive stools submitted by GPs. The
proportion of positive samples (2.1%) was consistent with
that in our study. The proportions of patients who used anti-
biotics in the previous 4 weeks and who were hospitalized in
the last 6 months were 52% and 45%, respectively. Unfortu-
nately, no information was provided on comorbidity, animal
contacts, follow-up and clinical characteristics of the diarrho-
eal illness other than stool frequency. Also, the authors men-
tioned the frequent occurrence of PCR ribotype 001, but
did not provide information on other PCR ribotypes found
and whether these are associated with hospital outbreaks.
The incidence rate of CO-CDI cannot be estimated from
our data, as it is unclear how many cases have been missed
because patients did not visit their GPs or GPs did not
perform diagnostic tests. Therefore, it is difﬁcult to compare
our ﬁndings with the results of surveillance studies of gastro-
enteritis in Dutch general practices [23,24], which did not
test for C. difﬁcile.
Interestingly, our data suggest that CO-CDI does not
directly result from the effects of healthcare-associated out-
breaks. We did not ﬁnd support for the hypothesis that an
animal reservoir plays a major role in CO-CDI. However, in
the region of Zwolle, PCR ribotype 078 was the most fre-
quently encountered strain. This strain has frequently been
found in recent surveillance studies of nosocomial CDI in The
Netherlands. It has also been found in farm animals and meat
products, and transmission from animals to humans seems
possible. It was isolated from stools of diarrhoeal piglets in
The Netherlands [25]. The city of Zwolle is situated in a rural
part of The Netherlands, and one could speculate that a link
between humans and animal cases exists in this area.
In conclusion, the prevalence of C. difﬁcile in stools of
patients with community-onset diarrhoea in The Netherlands
for which diagnostics are requested by their GPs is 1.5%. All
age groups can be affected, and many patients have not been
admitted to healthcare institutions or used antibiotics. Many
PCR ribotypes of C. difﬁcile that are not encountered in hos-
pital-associated outbreaks are found. Physicians, including
GPs, should be aware of the possibility of CDI outside of
the known risk factors.
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